

BCA. Refractoriness First-line Treatment for Blood Cell Autoimmunity

NIHR BioResource – Rare Diseases study project

Lead Investigator(s): Dr Nichola Cooper and Dr Quentin Hill

V1 19/07/2019

Summary

Autoimmune cytopenias are rare diseases where the immune system attacks blood cells, usually platelets or red blood cells and occasionally white blood cells. We do not know the cause of these diseases and they cause significant illness. Genomic analysis of these patients could help us to better understand the cause of disease, help with treatment decisions and also help design curative therapies.

Recruitment Criteria

Inclusion

Non-transient autoimmune haematological disorders (red cells and / or platelets and / or neutrophils).

Suspected or likely diagnosis of an autoimmune cause of the cytopenia which persists for >3 months and is **refractory to first-line treatment** following review by a haematologist.

Exclusion

Transient cytopenias in infants < 3 months of age.

Cytopenias which remain in remission after first-line treatment.